A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures

Table 1

Clinical and pathologic characteristics of patients with pancreaticobiliary malignancy. IHC staining grade for uPA and serum uPA values for 6 of 8 patients with pancreatic adenocarcinoma and 2 of 3 patients with cholangiocarcinoma overexpressed uPA on cytology obtained from ERCP brushings. Serum values correlated to intensity of staining.

Patient	Sex	Age (yrs)	Cancer Type	Tumor Size	CA 19-9 (U/mL)	IHC Grade	Serum uPA (ng/mL)
1	M	57	Pancreatic	3 cm	27.8	2+	1.18
2	M	35	Pancreatic	4.5 cm	348	3+	0.84
3	F	73	Pancreatic	5.2 cm	45.7	3+	5.86
4	M	71	Pancreatic	3.3 cm	450	2+	0.87
5	M	60	Pancreatic	3 cm	83.9	2+	0.2
6	M	39	Pancreatic	5 cm	126	2+	0.61
7	F	78	Pancreatic	3.0	<1.0	0	0.61
8	F	56	Pancreatic	4 cm	138	0	0.53
9	F	78	Cholangiocarcinoma	1.2	42	3+	0.98
10	M	82	Cholangiocarcinoma	1.0	830.3	2+	0.73
11	M	78	Cholangiocarcinoma	2 cm	52.3	0	0.52